Efalizumab: A Biological Agent for the Treatment of Psoriasis

Author(s): Sarah Hodulik, Suhail Hadi.

Journal Name: Reviews on Recent Clinical Trials

Volume 1 , Issue 2 , 2006

Become EABM
Become Reviewer

Abstract:

Efalizumab is a humanized, monoclonal IgG1 antibody that binds to the α-subunit of lymphocyte function associated antigen (LFA)-1, blocking the interaction between LFA-1 and intercellular adhesion molecule-1. The result is a reduction in T cell activation, an inhibition of the trafficking and recruitment of T cells to the dermis and epidermis, and a decrease in the reactivation of T cells at several steps in the psoriasis pathogenesis. The clinical responses seen in efalizumab trials have demonstrated that this medication is efficacious, especially in long-term treatment. Adverse events observed in efalizumab-treated patients have been minor. Psoriasis rebound following discontinuation of treatment, while serious, has been controlled through transition to other therapies. Subcutaneous injection allows for administration outside the clinic.

Keywords: Anti-CD11a, Biologic, Efalizumab, LFA-1, Psoriasis, Raptiva(™), T cell

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 1
ISSUE: 2
Year: 2006
Page: [165 - 168]
Pages: 4
DOI: 10.2174/157488706776876436
Price: $58

Article Metrics

PDF: 1